Copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2000
I read with great interest the article by Bonet et al1 regarding the benefits of vasodilating and nonvasodilating agents. Clearly, it would be useful clinically to know if vasodilating β-blockers such as carvedilol are more effective than less expensive, nonvasodilating β-blockers such as metoprolol.
The authors draw the conclusion that vasodilating β-blockers had a greater effect on overall mortality than nonvasodilating β-blockers. That conclusion is a matter of statistical interpretation and not wholly supported by the authors.
Stello B. β-Blockers in Congestive Heart Failure: Is There a Difference Between Classes?. Arch Intern Med. 2000;160(19):3005-3006. doi: